Document Detail


DHEA (Leland Stanford Junior University).
MedLine Citation:
PMID:  16180172     Owner:  NLM     Status:  PubMed-not-MEDLINE    
Abstract/OtherAbstract:
Genelabs is developing oral dehydroepiandrosterone (DHEA), for the potential treatment of systemic lupus erythematosus (SLE) in women. Results of a second phase III study, due for completion in March 1999, will determine whether Genelabs files an NDA in the US. Because of the public domain nature of DHEA, Genelabs is not certain that it will obtain patent protection. In the US it received Orphan Drug designation, providing seven years of exclusive marketing rights, and, in October 1996, Genelabs received US-05567696, covering the use of DHEA in lupus patients to reduce their dosage of concomitant corticosteroids. The US FDA has also granted Subpart E designation to DHEA, which permits expedited development. Genelabs licensed the product exclusively worldwide from Stanford University, which performed the early stage clinical studies. The Asian marketing rights have been licensed to Genelabs Biotechnology Ltd (GBL), a joint investment with the government of Taiwan.
Authors:
P Norman
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  IDrugs : the investigational drugs journal     Volume:  2     ISSN:  1369-7056     ISO Abbreviation:  IDrugs     Publication Date:  1999 Jan 
Date Detail:
Created Date:  2005-09-23     Completed Date:  2005-10-13     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100883655     Medline TA:  IDrugs     Country:  England    
Other Details:
Languages:  eng     Pagination:  59-64     Citation Subset:  -    
Affiliation:
Norman Consulting, Burnham, Buckinghamshire, SL1 8JW, UK. pn29@student.open.ac.uk
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Recent advances in non-peptidic RANTES antagonists.
Next Document:  ABX-CBL (Abgenix Inc).